MedTrace Logo

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

NCT01080209 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2015-02-20

Study results available
· View outcomes & findings →

Summary

This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

Conditions

  • Patients Who Participated in an Intravitreal Brimo PS DDS® Study

Interventions

DRUG

Brimo PS DDS®

Patients who received Brimo PS DDS® intravitreal implant in a previous study.

OTHER

Sham

Patients who recieved sham in a previous study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
NON_RANDOMIZED
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Philippines
  • Portugal
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01080209 on ClinicalTrials.gov